Behring Diagnostics looking for a partner ahead of possible flotation of minority stake
This article was originally published in Clinica
Executive Summary
Hoechst, the German pharmaceutical and chemicals group, announced unexpectedly wide-ranging reorganisation plans last week. In 1997, Hoechst will become a strategic management holding, with its entire operating business split into ten legally independent affiliates. One of these will be the company's diagnostics business, Behring Diagnostics. By teaming up with a partner, Hoechst chairman Jurgen Dormann hopes Behring will expand its product range and strengthen its position in America.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.